What Kohjin Bio does

Kohjin Bio Co., Ltd. is a Japanese biotechnology company founded in 1981 and headquartered in Sakado, Japan, with 101-250 employees. The firm specializes in regenerative medicine research, development, and manufacturing, with its core technology built around iPS (induced pluripotent stem) cell platforms applied to therapeutic applications. Historically a cell biology and microbial testing-focused entity, the company has more recently pivoted toward applied regenerative medicine, targeting the development of cell therapy products and the establishment of standardized manufacturing processes for these therapies.

Kohjin Bio's primary commercial focus is veterinary medicine, where it applies its iPS cell technology to develop cell therapy products for animal health — a vertical the company identifies as its primary segment, addressing the limited treatment options and lack of standardized cell therapy manufacturing in veterinary regenerative medicine. The company also explicitly pursues translational medicine, seeking to bridge veterinary and human applications of its cell therapy platform. No named commercial products, pricing model, or revenue figures are publicly disclosed.

In March 2026, Kohjin Bio entered into a three-party capital and business alliance with Vetanic (a veterinary-focused partner) and Sysmex Corporation (a major diagnostics and life sciences instrumentation company) to advance regenerative medicine research, development, and manufacturing in veterinary applications. The alliance combines Kohjin Bio's iPS cell platform, Vetanic's veterinary distribution capabilities, and Sysmex's diagnostic infrastructure, with an explicit forward-looking objective of establishing manufacturing processes and exploring translational pathways from animal to human therapies. Leadership consists of President and CEO Takahito Nakamura. The company remains privately held with no disclosed parent company.

Name

Kohjin Bio

Legal name

Kohjin Bio Co., Ltd.

Website

https://kohjin-bio.jp

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

101–250 employees

Short description

Kohjin Bio Co., Ltd. is a Japanese biotechnology firm (founded 1981) developing iPS cell-based regenerative medicine and cell therapy manufacturing, with a primary focus on veterinary medicine applications. The company partners with Vetanic and Sysmex Corporation (March 2026 alliance) to commercialize animal cell therapies and pursue translational human applications.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Regenerative medicine
• IPS cell technology
• Cell therapy products
• Microbial testing products
• Immunotherapy research

Headquarters

HQ city

Sakado

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Kohjin Bio is a Japanese biotechnology company that develops regenerative medicine and immunotherapy research, and manufactures cell therapy products using iPS cell technology. It also provides microbial testing products and establishes manufacturing processes for regenerative medicine.

Product overview

Kohjin Bio Co., Ltd. is a company engaged in regenerative medicine research, development, and manufacturing, with a focus on iPS cell technology. The company is involved in developing cell therapy products and establishing manufacturing processes in partnership with Vetanic and Sysmex Corporation. The source material does not provide specific named products or a detailed product portfolio — only a press release regarding a capital and business alliance for veterinary regenerative medicine research.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Therapy Products (iPS cell-based) Cell therapy products developed using iPS cell technology for regenerative medicine applications, including veterinary regenerative medicine treatments. Developed in collaboration with Vetanic and Sysmex Corporation.
• Microbial Testing Products Microbial testing products provided for biotechnology and life science applications.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• VetaniccoreStrategic or Co-development Partner · 31 March 2026Vetanic has entered into a capital and business alliance with Kohjin Bio Co., Ltd. to advance regenerative medicine research, development, and manufacturing in veterinary medicine. The collaboration leverages iPS cell technology to develop cell therapy products, establish manufacturing processes, and explore translational medicine between veterinary and human medicine.
• Sysmex CorporationcoreStrategic or Co-development Partner · 31 March 2026Sysmex Corporation has entered into a capital and business alliance with Vetanic and Kohjin Bio Co., Ltd. The three-party collaboration aims to advance regenerative medicine research, development, and manufacturing in veterinary medicine, leveraging iPS cell technology to develop cell therapy products and establish manufacturing processes.

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Astellas Pharma: Major Japanese pharmaceutical company with regenerative medicine and cell therapy programs (including Universal Cells acquisition); operates broadly in the same therapeutic space with much larger resources.
• Sysmex Corporation: Major listed Japanese diagnostics and life sciences company that has entered a capital and business alliance with Kohjin Bio, bringing overlapping regenerative medicine R&D capabilities and broader commercial scale.
• Sumitomo Pharma: Large Japanese pharmaceutical company with regenerative medicine and cell therapy programs (e.g., via former Sumitomo Dainippon Pharma); comparable as a Japanese player pursuing similar therapeutic modalities.

Emerging players

• Cynata Therapeutics: Clinical-stage company developing iPSC-derived mesenchymal stem cell therapies; shares iPSC platform technology with Kohjin Bio but focuses on human indications.
• Century Therapeutics: Clinical-stage company developing iPSC-derived cell therapies for cancer and other indications; comparable as an iPSC-platform cell therapy peer, though targeting different therapeutic areas.

Direct peers

• FUJIFILM Cellular Dynamics: Developer and manufacturer of iPS cell-derived cell therapies and related products; directly comparable in core technology platform (iPSC) and therapeutic focus.
• Healios K.K. Japanese regenerative medicine company developing stem cell therapies for human indications; comparable in cell therapy modality and Japanese regulatory pathway focus.
• Mesoblast Limited: Commercial-stage regenerative medicine company developing cell therapies for inflammatory and immune-mediated diseases; comparable in cell therapy modality and regenerative medicine positioning.
• Pluristem Therapeutics: Cell therapy company developing placenta-derived cell therapies for regenerative medicine indications; comparable as a clinical-stage regenerative medicine peer with similar therapeutic focus areas.
• Vetanic: Japanese veterinary regenerative medicine company partnering directly with Kohjin Bio on iPS cell-based cell therapies for animals; both target the same niche and product category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kohjin Bio